Innoviva, Inc. (INVA)

15,26 +0,27 (+1,80%) Alla chiusura: 04:00PM EDT

Innoviva, Inc.

1350 Old Bayshore Highway
Suite 400
Burlingame, CA 94010
United States
650 238 9600
https://www.inva.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 112

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Pavel Raifeld C.F.A.	Chief Executive Officer	754,67k	N/D	1984
Ms. Marianne Zhen CPA	Chief Accounting Officer & Secretary	530,21k	N/D	1969
Mr. Stephen Basso M.B.A.	Chief Financial Officer	N/D	N/D	1966

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Governance aziendale

L'ISS Governance QualityScore di Innoviva, Inc. al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.